

# Arnaud Uguen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2504891/arnaud-uguen-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73  
papers

514  
citations

13  
h-index

19  
g-index

81  
ext. papers

652  
ext. citations

3.3  
avg, IF

4.18  
L-index

#	Paper	IF	Citations
73	ROS1 fusions in cancer: a review. <i>Future Oncology</i> , <b>2016</b> , 12, 1911-28	3.6	49
72	A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma. <i>Diagnostic Pathology</i> , <b>2015</b> , 10, 195	3	47
71	Evaluation of a fast and fully automated platform to diagnose and mutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one day. <i>Journal of Clinical Pathology</i> , <b>2017</b> , 70, 544-549	3.9	30
70	A review on the Idylla platform: towards the assessment of actionable genomic alterations in one day. <i>Journal of Clinical Pathology</i> , <b>2018</b> , 71, 757-762	3.9	30
69	NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas. <i>Diagnostic Pathology</i> , <b>2015</b> , 10, 121	3	28
68	Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice. <i>Human Pathology</i> , <b>2015</b> , 46, 1582-91	3.7	26
67	A Mismatch Repair-Deficient Hepatoid Adenocarcinoma of the Lung Responding to Anti-PD-L1 Durvalumab Therapy Despite no PD-L1 Expression. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, e120-e122	8.9	20
66	Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma. <i>Acta Dermato-Venereologica</i> , <b>2018</b> , 98, 44-49	2.2	16
65	Microsatellite instability diagnosis using the fully automated Idylla platform: feasibility study of an in-house rapid molecular testing ancillary to immunohistochemistry in pathology laboratories. <i>Journal of Clinical Pathology</i> , <b>2019</b> , 72, 830-835	3.9	15
64	Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2015</b> , 467, 47-54	5.1	14
63	B-cell and T-cell quantification in minor salivary glands in primary Sjögren's syndrome: development and validation of a pixel-based digital procedure. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 21	5.7	14
62	ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?. <i>Lung Cancer</i> , <b>2016</b> , 91, 67-9	5.9	14
61	Asbestos-related lung cancers: A retrospective clinical and pathological study. <i>Molecular and Clinical Oncology</i> , <b>2017</b> , 7, 135-139	1.6	13
60	Histopathological factors help to predict lymph node metastases more efficiently than extra-nodal recurrences in submucosa invading pT1 colorectal cancer. <i>Scientific Reports</i> , <b>2019</b> , 9, 8342	4.9	12
59	A Rare Case of ROS1 and ALK Double Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, e71-e72	8.9	11
58	Duplication of SOX3 (Xq27) may be a risk factor for Neural Tube Defects. <i>American Journal of Medical Genetics, Part A</i> , <b>2015</b> , 167, 1676-8	2.5	10
57	Identification of a novel population in high-grade oligodendroglial tumors not deleted on 1p/19q using array CGH. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 109, 405-13	4.8	10

56	Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. <i>Human Pathology</i> , <b>2018</b> , 72, 135-143	3.7	10
55	A Diagnostic Algorithm Combining Immunohistochemistry and Molecular Cytogenetics to Diagnose Challenging Melanocytic Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2018</b> , 26, 714-720	1.9	9
54	ALK ambiguous-positive non-small cell lung cancers are tumors challenged by diagnostic and therapeutic issues. <i>Oncology Reports</i> , <b>2016</b> , 36, 1427-34	3.5	9
53	The p16-Ki-67-HMB45 Immunohistochemistry Scoring System is Highly Concordant With the Fluorescent In Situ Hybridization Test to Differentiate Between Melanocytic Nevi and Melanomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2018</b> , 26, 361-367	1.9	9
52	Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e647-e653	4.9	8
51	Non-secretory breast carcinomas lack NTRK rearrangements and TRK protein expression. <i>Pathology International</i> , <b>2019</b> , 69, 94-96	1.8	8
50	Financial implications of Idylla testing in colorectal cancer, lung cancer and melanoma: a French laboratory point of view. <i>Journal of Clinical Pathology</i> , <b>2017</b> , 70, 906-907	3.9	7
49	Screening for NTRK-rearranged Tumors Using Immunohistochemistry: Comparison of 2 Different pan-TRK Clones in Melanoma Samples. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2020</b> , 28, 194-196	1.9	7
48	Severe hydrocephalus caused by diffuse leptomeningeal and neurocutaneous melanocytosis of antenatal onset: a clinical, pathologic, and molecular study of 2 cases. <i>Human Pathology</i> , <b>2015</b> , 46, 1189-96	3.7	6
47	Evaluation of , and mutational status and microsatellite instability in early colorectal carcinomas invading the (pT1): towards an in-house molecular prognostication for pathologists?. <i>Journal of Clinical Pathology</i> , <b>2020</b> , 73, 741-747	3.9	6
46	NRASQ61R and BRAFV600E Mutation-specific Immunohistochemistry Is a Helpful Tool to Diagnose Metastatic Undifferentiated/Dedifferentiated Melanomas. <i>American Journal of Surgical Pathology</i> , <b>2016</b> , 40, 1004-5	6.7	6
45	BRAFV600E and NRASQ61R Homogeneity in Melanoma Tumors. <i>Journal of Investigative Dermatology</i> , <b>2016</b> , 136, 337-8	4.3	6
44	High reproducibility is attainable in assessing histoprognostic parameters of pT1 colorectal cancer using routine histopathology slides and immunohistochemistry analyses. <i>Pathology</i> , <b>2019</b> , 51, 46-54	1.6	6
43	Detection of Mismatch Repair Deficiency in Colorectal Cancers: Is It Really Time to Eliminate Immunohistochemistry?. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 376-377	2.2	5
42	EPR17341 and A7H6R pan-TRK Immunohistochemistry Result in Highly Different Staining Patterns in a Series of Salivary Gland Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2020</b> , 28, 719-724	1.9	5
41	Fluorescence hybridization testing of chromosomes 6, 8, 9 and 11 in melanocytic tumors is difficult to automate and reveals tumor heterogeneity in melanomas. <i>Oncology Letters</i> , <b>2016</b> , 12, 2734-2741	2.6	5
40	MET Immunohistochemistry Should Be Avoided in Selecting Non-small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, e418-e420	4.9	4
39	False ALK Rearrangement Signals in Inflammatory Cells: A Pitfall in the Interpretation of ALK Fluorescence In Situ Hybridization in Non-Small Cell Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2017</b> , 25, 668-670	1.9	3

38	ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e73-e74	4.9	3
37	Toward a Molecular Diagnosis in a Single Day for Patients With Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e537-e538	4.9	3
36	Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent In Situ Hybridization: The Importance of Probe Design. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, e83-5	8.9	3
35	MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories. <i>Human Pathology</i> , <b>2021</b> , 114, 99-109	3.7	3
34	About HER2 monitoring using liquid biopsies in patients with gastric cancer. <i>Gastric Cancer</i> , <b>2017</b> , 20, 1011-1012	7.6	2
33	Decalcification can cause the failure of BRAF molecular analyses and anti-BRAFV600E VE1 immunohistochemistry. <i>Pathology International</i> , <b>2019</b> , 69, 219-223	1.8	2
32	BRAF p.V600E immunohistochemistry in challenging samples: about false-positive and false-negative results. <i>Human Pathology</i> , <b>2015</b> , 46, 1064-5	3.7	2
31	Another Case of Pacinian Corpuscle in a Lymph Node. <i>Anatomical Record</i> , <b>2018</b> , 301, 561-562	2.1	2
30	Is SP174 Immunohistochemistry an Interesting Ancillary Tool to Determine RAS Mutational Status in Colorectal Carcinoma?. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2017</b> , 25, e25-e26	1.9	1
29	About RAS mutation-specific immunohistochemistry in formalin-fixed, paraffin-embedded tumor samples. <i>Human Pathology</i> , <b>2017</b> , 60, 208-209	3.7	1
28	Testing for fusions in patients with advanced // wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy. <i>Journal of Clinical Pathology</i> , <b>2020</b> , 73, 116-119	3.9	1
27	GNA11-mutated and BAP1-negative Melanomas Ex Blue Naevi: A Particularly Aggressive Entity. <i>Acta Dermato-Venereologica</i> , <b>2017</b> , 97, 743-744	2.2	1
26	Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 736-739	3.3	1
25	Asbestos-related lung cancers are rarely associated with , and rearrangements. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	1
24	Reasons for pathologic examination of sleeve gastrectomy remnants in France. <i>American Journal of Surgery</i> , <b>2018</b> , 216, 1031-1032	2.7	1
23	Targeting BRAF mutants in clear-cell sarcomas of soft tissue: beyond sarcoma or melanoma classification. <i>Investigational New Drugs</i> , <b>2016</b> , 34, 253-4	4.3	1
22	Avoiding non-contributive molecular results in cancer samples: proposal of a score-based approach for sample choice. <i>Pathology</i> , <b>2019</b> , 51, 524-528	1.6	1
21	Costs of ALK, ROS1, EGFR, and KRAS testing in non-small cell lung cancer: About different strategies in France. <i>Cancer Cytopathology</i> , <b>2017</b> , 125, 876	3.9	1

20	Another Point of View About Cyclin D1 and p16 Expression in Blue Nevi and Malignant Melanomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2017</b> , 25, e70-e71	1.9	1
19	Upfront immunohistochemistry improves specificity of Helicobacter pylori diagnosis. A French pathology laboratory point of view. <i>Helicobacter</i> , <b>2017</b> , 22, e12424	4.9	1
18	Comment on: "Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma". <i>Molecular Diagnosis and Therapy</i> , <b>2017</b> , 21, 693-694	4.5	1
17	Comment on: "Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study)". <i>Targeted Oncology</i> , <b>2017</b> , 12, 839-840	5	1
16	VE1 Immunohistochemistry Fails to Detect Most of the Non-BRAFV600E Mutations in Melanoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2016</b> , 24, e98-e99	1.9	1
15	Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing. <i>Pathology</i> , <b>2021</b> ,	1.6	1
14	KRAS and BRAF Double Mutations and Functional Classes of BRAF Mutations in Non-small-cell Lung Cancers. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e240-e242	4.9	0
13	Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX recurrence score using Magee Equations and Magee Decision Algorithm. <i>Human Pathology</i> , <b>2021</b> , 108, 51-59	3.7	0
12	BRAF Mutational Intertumoral Discrepancies: Think About Technical Limitations Instead of Mutational Heterogeneity. <i>American Journal of Dermatopathology</i> , <b>2017</b> , 39, 66	0.9	
11	About concomitant KRAS and other molecular alterations in non-small cell lung cancers. <i>Human Pathology</i> , <b>2019</b> , 87, 115-116	3.7	
10	The rarity of concomitant genetic alterations in lung cancer. <i>Modern Pathology</i> , <b>2018</b> , 31, 539-540	9.8	
9	Standardized fixation process is crucial to permit molecular analyses in formalin-fixed and paraffin-embedded melanoma samples. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2016</b> , 54, e359-e360 <sup>5.9</sup>		
8	About MET expression and other biomarkers in non-small cell lung cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2017</b> , 471, 685-686	5.1	
7	A French point of view about the cost effectiveness of RASQ61R immunohistochemistry in colorectal cancer. <i>Pathology</i> , <b>2017</b> , 49, 810-811	1.6	
6	Each RET Break-Apart Fluorescence In Situ Hybridization Probe Requires Proper Interpretation Criteria. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, e55	8.9	
5	A Place for BRAFV600E Mutation-specific Immunohistochemistry Alongside Cell-free DNA Mutation Detection in Melanoma. <i>Acta Dermato-Venereologica</i> , <b>2016</b> , 96, 426-7	2.2	
4	Are Comprehensive Next-generation Sequencing Analyses Really Required for the Management of Patients With Melanoma to Date?. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2018</b> , 26, e24	1.9	
3	Pathologie moléculaire des mélanomes : applications pratiques. <i>Revue Francophone Des Laboratoires</i> , <b>2018</b> , 2018, 34-39	0	

- 2 Random Colocalization and Split of ALK Break Apart Probe Signals: Potential Concerns in the Real-Life Diagnosis of Non-Small-Cell Lung Cancer. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2018**, 93, 980-981 4.6
- 1 Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times. *European Respiratory Journal*, **2018**, 51, 13.6